These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation. Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630 [TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches. Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693 [TBL] [Abstract][Full Text] [Related]
8. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study. Uzuner U; Akkus E; Kocak A; Çelik Uzuner S J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994 [TBL] [Abstract][Full Text] [Related]
9. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. Wakchaure PD; Ghosh S; Ganguly B J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493 [TBL] [Abstract][Full Text] [Related]
10. Identification of Natural Inhibitors Against SARS-CoV-2 Drugable Targets Using Molecular Docking, Molecular Dynamics Simulation, and MM-PBSA Approach. Kushwaha PP; Singh AK; Bansal T; Yadav A; Prajapati KS; Shuaib M; Kumar S Front Cell Infect Microbiol; 2021; 11():730288. PubMed ID: 34458164 [TBL] [Abstract][Full Text] [Related]
11. Emetine, a potent alkaloid for the treatment of SARS-CoV-2 targeting papain-like protease and non-structural proteins: pharmacokinetics, molecular docking and dynamic studies. Snoussi M; Redissi A; Mosbah A; De Feo V; Adnan M; Aouadi K; Alreshidi M; Patel M; Kadri A; Noumi E J Biomol Struct Dyn; 2022; 40(20):10122-10135. PubMed ID: 34254564 [TBL] [Abstract][Full Text] [Related]
12. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease. Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340 [TBL] [Abstract][Full Text] [Related]
13. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988 [TBL] [Abstract][Full Text] [Related]
14. Binding properties of selective inhibitors of P323L mutated RdRp of SARS-CoV-2: a combined molecular screening, docking and dynamics simulation study. Chinnamadhu A; Ramakrishnan J; Suresh S; Poomani K J Biomol Struct Dyn; 2024 May; 42(8):4283-4296. PubMed ID: 37301607 [TBL] [Abstract][Full Text] [Related]
15. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. Rafi MO; Bhattacharje G; Al-Khafaji K; Taskin-Tok T; Alfasane MA; Das AK; Parvez MAK; Rahman MS J Biomol Struct Dyn; 2022 May; 40(8):3711-3730. PubMed ID: 33251975 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19). El-Demerdash A; Metwaly AM; Hassan A; Abd El-Aziz TM; Elkaeed EB; Eissa IH; Arafa RK; Stockand JD Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33808721 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from Nivetha R; Bhuvaragavan S; Muthu Kumar T; Ramanathan K; Janarthanan S J Biomol Struct Dyn; 2022; 40(21):11070-11081. PubMed ID: 34431451 [TBL] [Abstract][Full Text] [Related]
18. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. Ancy I; Sivanandam M; Kumaradhas P J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2. Mishra A; Rathore AS Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060 [TBL] [Abstract][Full Text] [Related]
20. Computational identification of potential inhibitory compounds in Indian medicinal and aromatic plant species against major pathogenicity determinants of SARS-CoV-2. Sharma S; Sharma A; Bhattacharyya D; Chauhan RS J Biomol Struct Dyn; 2022; 40(24):14096-14114. PubMed ID: 34766880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]